Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2018 | 09-2018 | 06-2018 | 03-2018 | 12-2017 | |
| Sales | 1,889 | 1,583 | 1,971 | 1,759 | 1,759 |
| Cost of Goods | 1,108 | 949 | 1,208 | 1,069 | 1,063 |
| Gross Profit | 782 | 634 | 763 | 690 | 696 |
| Operating Expenses | 3,307 | 3,277 | 2,905 | 2,241 | 1,858 |
| Operating Income | -2,418 | -1,695 | -1,934 | -1,482 | -1,099 |
| Interest Expense | 84 | 93 | 137 | 400 | 199 |
| Other Income | 6 | 8 | 6 | 3 | 5 |
| Pre-tax Income | -2,496 | -1,780 | -2,065 | -1,878 | -1,293 |
| Income Tax | 1 | 100 | -2 | 4 | -14 |
| Net Income Continuous | -2,497 | -1,880 | -2,063 | -1,883 | -1,279 |
| Net Income | $-2,497 | $-1,880 | $-2,063 | $-1,883 | $-1,279 |
| EPS Basic Total Ops | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 |
| EPS Basic Continuous Ops | -0.12 | -0.09 | -0.10 | -0.11 | -0.08 |
| EPS Diluted Total Ops | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 |
| EPS Diluted Continuous Ops | -0.12 | -0.09 | -0.10 | -0.11 | -0.08 |
| EBITDA(a) | $-2,525 | $-1,621 | $-1,859 | $-1,408 | $-1,024 |